<?xml version="1.0" encoding="UTF-8"?>
<fn-group>
 <fn id="fn2-1031806">
  <p>Check the online version for the most updated information on this article, online supplements, and information on authorship &amp; disclosures: 
   <ext-link ext-link-type="uri" xlink:href="www.haematologica.org/content/103/11/1806" xmlns:xlink="http://www.w3.org/1999/xlink">www.haematologica.org/content/103/11/1806</ext-link>
  </p>
 </fn>
 <fn id="fn3-1031806">
  <p>
   <bold>Funding</bold>
  </p>
  <p>This work was also supported in part by grants and contracts to H-PK from the NIH HHSN2680004 and HL122173 and by funds to JEA from the Fred Hutch. This research was also funded in part through the NIH/NCI Cancer Center Support Grant P30 CA015704. H-PK is a Markey Molecular Medicine Investigator and received support as the inaugural recipient of the José Carreras/E. Donnall Thomas Endowed Chair for Cancer Research and the Fred Hutch Endowed Chair for Cell and Gene Therapy. JEA and H-PK are co-inventors on U.S. Provisional Patent Applications #62/491,116 and #62/503,801 "Novel Manufacturing of Gene Corrected Autologous Blood Cells for Gene Therapy.” JEA has previously served as a consultant for Rocket Pharmaceuticals. H-PK is an active consultant for Rocket Pharmaceuticals. The other authors declare that they have no competing interests.</p>
 </fn>
</fn-group>
